Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes

Molecular Immunology

Volumn 43, Issue 14, 2006, Pages 2169-2179

  Ghosh, Sharmistha ^a   Preet, Anju ^a   Groopman, Jerome E ^a   Ganju, Ramesh K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cannabinoids; Chemotaxis; Migration; Signaling; T lymphocytes

Indexed keywords

2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; STROMAL CELL DERIVED FACTOR 1; ALPHA CHEMOKINE; CALCIUM; CANNABINOID; CYCLOHEXANE DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; INDOLE DERIVATIVE; IODOPRAVADOLINE; JHW 015; MITOGEN ACTIVATED PROTEIN KINASE; PHENOL DERIVATIVE;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL MIGRATION; CHEMOTAXIS; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOMODULATION; INHIBITION KINETICS; LEUKEMIA CELL LINE; MOLECULAR MECHANICS; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; T LYMPHOCYTE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; IMMUNOLOGY; METABOLISM; NEUTROPHIL CHEMOTAXIS; PHYSIOLOGY; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

CALCIUM; CANNABINOIDS; CHEMOKINES, CXC; CHEMOTAXIS, LEUKOCYTE; CYCLOHEXANES; ENDOTHELIUM, VASCULAR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDOLES; JURKAT CELLS; MATRIX METALLOPROTEINASE 9; MITOGEN-ACTIVATED PROTEIN KINASES; PHENOLS; RECEPTOR, CANNABINOID, CB2; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; UMBILICAL VEINS;

EID: 33744827120     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2006.01.005     Document Type: Article

References (74)

1. Abadji V., Lin S., Taha G., Griffin G., Stevenson L.A., Pertwee R.G., and Makriyannis A. (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J. Med. Chem. 37 (1984) 1889-1893
2. Aiuti A., Webb I.J., Bleul C., Springer T., and Gutierrez-Ramos J.C. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J. Exp. Med. 185 (1997) 111-120
3. Alessi D.R., Cuenda A., Cohen P., Dudley D.T., and Saltiel A.R. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270 (1995) 27489-27494
4. Arthur M.J., Stanley A., Iredale J.P., Rafferty J.A., Hembry R.M., and Friedman S.L. Secretion of 72 kDa type IV collagenase/gelatinase by cultured human lipocytes. Analysis of gene expression, protein synthesis and proteinase activity. Biochem. J. 287 (1992) 701-707
5. Baczynsky W.O., and Zimmerman A.M. Effects of delta 9-tetrahydrocannabinol, cannabinol and cannabidiol on the immune system in mice. II. In vitro investigation using cultured mouse splenocytes. Pharmacology 26 (1983) 12-19
6. Bell M.R., D'Ambra T.E., Kumar V., Eissenstat M.A., Herrmann Jr. J.L., Wetzel J.R., Rosi D., Philion R.E., Daum S.J., Hlasta D.J., et al. Antinociceptive (aminoalkyl)indoles. J. Med. Chem. 34 (1991) 1099-1110
7. Berdyshev E.V. Cannabinoid receptors and the regulation of immune response. Chem. Phys. Lipids 108 (2000) 169-190
8. Blázquez C., Casanova M.L., Planas A., Gomez del Pulgar T., Villanueva C., Fernández-Aceñero M.J., Aragones J., Huffman J.W., Jorcano J.L., and Guzmán M. Inhibition of tumor angiogenesis by cannabinoids. FASEB J. 17 (2003) 529-531
9. Bleul C.C., Farzan M., Choe H., Parolin C., Clark-Lewis I., Sodroski J., and Springer T.A. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 382 (1996) 829-833
10. Bleul C.C., Fuhlbrigge R.C., Casasnovas J.M., Aiuti A., and Springer T.A. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF1). J. Exp. Med. 184 (1996) 1101-1109
11. Buckley N.E., McCoy K.L., Mezey E., Bonner T., Zimmer A., Felder C.C., Glass M., and Zimmer A. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur. J. Pharmacol. 396 (2000) 141-149
12. Burnette-Curley D., Marciano-Cabral F., Fischer-Stenger K., and Cabral G.A. Delta-9-tetrahydrocannabinol inhibits cell contact-dependent cytotoxicity of Bacillus Calmette-Guérin-activated macrophages. Int. J. Immunopharmacol. 15 (1993) 371-382
13. Cherla R.P., and Ganju R.K. Stromal cell-derived factor 1 alpha-induced chemotaxis in T cells is mediated by nitric oxide signaling pathways. J. Immunol. 166 (2001) 3067-3074
14. 2, peripheral cannabinoid receptor. J. Pharmacol. Exp. Ther. 291 (1999) 837-844
15. Consroe P. Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol. Dis. 5 (1998) 534-551
16. Denis K., and Verweij J. Matrix metalloproteinase inhibitors: present achievements and future prospects. Invest. New Drugs 15 (1997) 175-185
17. Devane W.A., Dysarz F.A., Johnson M.R., Melvin L.S., and Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34 (1988) 605-613
18. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., and Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
19. Engelhardt B., and Wolburg H. Transendothelial migration of leukocytes: through the front door or around the side of the house?. Eur. J. Immunol. 34 (2004) 2955-2963
20. Felder C.C., Nielsen A., Briley E.M., Palkovits M., Priller J., Axelrod J., Nguyen D.N., Richardson J.M., Riggin R.M., Koppel G.A., Paul S.M., and Becker G.W. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett. 393 (1996) 231-235
21. Feng Y., Broder C.C., Kennedy P.E., and Berger E.A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272 (1996) 872-877
22. Foxman E.F., Campbell J.J., and Butcher E.C. Multistep navigation and the combinatorial control of leukocyte chemotaxis. J. Cell Biol. 139 (1997) 1349-1360
23. Goetzl E.J., Banda M.J., and Leppert D. Matrix metalloproteinases in immunity. J. Immunol. 156 (1996) 1-4
24. 1). J. Pharmacol. Exp. Ther. 289 (1999) 1427-1433
25. 2 receptor. Bioorg. Med. Chem. 7 (1999) 2905-2914
26. 2 receptor. J. Med. Chem. 39 (1996) 3875-3877
27. Jordà M.A., Verbakel S.E., Valk P.J.M., Vankan-Berkhoudt Y.V., Maccarrone M., Finazzi-Agró A., Löwenberg B., and Delwel R. Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol. Blood 99 (2002) 2786-2793
28. Joseph J., Niggemann B., Zaenker K.S., and Entschladen F. Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunol. Immunother. 53 (2004) 723-728
29. Kahn J., Byk T., Jansson-Sjostrand L., Petit I., Shivtiel S., Nagler A., Hardan I., Deutsch V., Gazit Z., Gazit D., Karlsson S., and Lapidot T. Overexpression of CXCR4 on human CD34+ progenitors increases their proliferation, migration, and NOD/SCID repopulation. Blood 103 (2004) 2942-2949
30. 2 receptor-dependent mechanism. J. Biol. Chem. 278 (2003) 24469-24475
31. Klein T.W., Newton C.A., and Friedman H. Cannabinoids and the immune system. Pain Res. Manage. 6 (2001) 95-101
32. Klein T.W., Newton C., and Friedman H. Cannabinoid receptors and immunity. Immunol. Today 8 (1998) 373-381
33. Klein T.W., Newton C., Snella E., Friedman H., Ader R., et al. Marijuana, the cannabinoid system and immunomodulation. Psychoneuroimmunology vol. 1 (2000), Academic Press, New York, NY
34. Klein T.W., Newton C., Widen R., and Friedman H. The effect of delta-9-hydrocannabinol and 11-hydroxy-delta-9-tetrahydrocannabinol on T-lymphocyte and B-lymphocyte mitogen response. J. Immunopharmacol. 7 (1985) 451-466
35. Klein T.W., Friedman H., and Specter S. Marijuana, immunity and infection. J. Neuroimmunol. 83 (1998) 102-115
36. Klein T.W., Kawakami Y., Newton C., and Friedman H. Marijuana components suppress induction and cytolytic function of murine cytotoxic T cells in vitro and in vivo. J. Toxicol. Environ. Health 32 (1991) 465-477
37. Leppert D., Waubant E., Galardy R., Bunnett N.W., and Hauser S.L. T Cell gelatinases mediate basement membrane transmigration in vitro. J. Immunol. 154 (1995) 4379-4389
38. Liang Z., Wu T., Lou H., Yu X., Taichman R.S., Lau S.K., Nie S., Umbreit J., and Shim H. Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res. 64 (2004) 4302-4308
39. Lo I.C., Shih J.M., and Jiang M.J. Reactive oxygen species and ERK1/2 mediate monocyte chemotactic protein-1-stimulated smooth muscle cell migration. J. Biomed. Sci. 12 (2005) 337-388
40. Madri J.A., and Graesser D. Cell migration in the immune system: the evolving inter-related roles of adhesion molecules and proteinases. Dev. Immunol. 7 (2000) 103-116
41. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
42. 2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100 (2002) 627-634
43. Melvin L.S., Johnson M.R., Harbert C.A., Milne G.M., and Weissman A. A cannabinoid derived prototypical analgesic. J. Med. Chem. 27 (1984) 67-71
44. Middleton J., Patterson A.M., Gardner L., Schmutz C., and Ashton B.A. Leukocyte extravasation: chemokine transport and presentation by the endothelium. Blood 100 (2002) 3853-3860
45. Moser B., and Willimann K. Chemokines: role in inflammation and immune surveillance. Ann. Rheum. Dis. 63 (2004) ii84-ii89
46. Moser B., Wolf M., Walz A., and Loetscher P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol. 25 (2004) 75-84
47. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
48. Munson A.E., Levy J.A., Harris L.S., and Dewey W.L. Effects of delta-9-hydrocannabinol on the immune system. In: Braude M.C., and Szara S. (Eds). The Pharmacology of Marijuana (1976), Raven Press, New York, NY
49. Nagasawa T., Hirota S., Tachibana K., Takakura N., Nishikawa S., Kitamura Y., Yhida N., Kikutani H., and Kishimoto T. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382 (1996) 635-638
50. Nahas G.G., Suciu-Foca N., Arnaud J.P., and Morishima A. Inhibition of cellular mediated immunity in marijuana smokers. Science 183 (1974) 419-420
51. Nong L., Newton C., Cheng Q., Friedman H., Roth M.D., and Klein T.W. Altered cannabinoid receptor mRNA expression in peripheral blood mononuclear cells from marijuana smokers. J. Neuroimmunol. 127 (2002) 169-176
52. Pertwee R.G. Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem. 6 (1999) 635-664
53. Pertwee R., Griffin G., Fernando S., Li X., Hill A., and Makriyannis A. AM630, a competitive cannabinoid receptor antagonist. Life Sci. 56 (1995) 1949-1955
54. Rao G.K., Zhang W., and Kaminski N.E. Cannabinoid receptor-mediated regulation of intracellular calcium by delta(9)-tetrahydrocannabinol in resting T cells. J. Leukoc. Biol. 75 (2004) 884-892
55. 2 cannabinoid receptors of L759633, L759656, and AM630. Br. J. Pharmacol. 126 (1999) 665-672
56. 2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol. Appl. Pharmacol. 142 (1997) 278-287
57. Schwarz H., Blanco F.J., and Lotz M. Anadamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. J. Neuroimmunol. 55 (1994) 107-115
58. Shapiro S.D. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr. Opin. Cell Biol. 10 (1998) 602-608
59. Smith S.R., Denhardt G., and Terminelli C. The antiinflammatory activities of cannabinoid receptor ligand in mouse peritonitis models. Eur. J. Pharmacol. 432 (2001) 107-119
60. Sofia R.D., Knobloch L.C., and Vassar H.B. The anti-edema activity of various naturally occurring cannabinoids. Res. Commun. Chem. Pathol. Pharmacol. 6 (1973) 909-918
61. Sofia R.D., Nalepa S.D., Vassar H.B., and Knobloch L.C. Comparative anti-phlogistic activity of delta 9-tetrahydrocannabinol, hydrocortisone and aspirin in various rat paw edema models. Life Sci. 15 (1974) 251-260
62. Sofia R.D., Nalepa S.D., Harakal J.J., and Vassar H.B. Anti-edema and analgesic properties of delta9-tetrahydrocannabinol (THC). J. Pharmacol. Exp. Ther. 186 (1973) 646-655
63. 1 cannabinoid receptor-mediated cell migration. J. Pharmacol. Exp. Ther. 294 (2000) 204-209
64. Springer T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76 (1994) 301-314
65. Stupack D.G., Cho S.Y., and Klemke R.L. Molecular signaling mechanisms of cell migration and invasion. Immunol. Res. 21 (2000) 83-88
66. Sugiura T., and Waku K. Cannabinoid receptors and their endogenous ligands. J. Biochem. (Tokyo) 132 (2002) 7-12
67. Tachibana K., Hirota S., Iizasa H., Yoshida H., Kawabata K., Kataoka Y., Kitamura Y., Matsushima K., Yoshida N., Nishikawa S., Kishimoto T., and Nagasawa T. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 393 (1998) 591-594
68. Terakawa M., Tomimori Y., Goto M., Hayashi Y., Oikawa S., and Fukuda Y. Eosinophil migration induced by mast cell chymase is mediated by extracellular signal-regulated kinase pathway. Biochem. Biophys. Res. Commun. 332 (2005) 969-975
69. Turk R.F., Manno J.E., Jain N.C., and Forney R.B. The identification, isolation, and preservation of delta-9-tetrahydrocannabinol (delta-9-THC). J. Pharm. Pharmacol. 23 (1971) 190-195
70. Uhm J.H., Dooley N.P., Stuve O., Francis G.S., Duquette P., Antel J.P., and Yong V.W. Migratory behavior of lymphocytes isolated from multiple sclerosis patients: effects of interferon beta-1b therapy. Ann. Neurol. 46 (1999) 319-324
71. Vande Broek I., Asosingh K., Allegaert V., Leleu X., Facon T., Vanderkerken K., Van Camp B., and Van Riet I. Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through up-regulation of MMP-9: evidence for a role of hepatocyte growth factor. Leukemia 8 (2004) 976-982
72. Walter L., Franklin A., Witting A., Wade C., Xie Y., Kunos G., Mackie K., and Stella N. Non-psychotropic cannabinoid receptors regulate microglial cell migration. J. Neurosci. 23 (2003) 1398-1405
73. Zou Y.R., Kottmann A.H., Kuroda M., Taniuchi I., and Littman D.R. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 393 (1998) 595-599
74. Zurier R.B., Rossetti R.G., Lane J.H., Goldberg J.M., Hunter S.A., and Burstein S.H. Dimethylheptyl-THC-11 oic acid: a non-psychoactive antiinflammatory agent with a cannabinoid template structure. Arthritis Rheum. 41 (1998) 163-170